The Pearsanta’s MET diagnostic test uses a blood-based biomarker for detecting mitochondrial DNA for diagnosing endometriosis ...

Aditxt (NASDAQ: ADTX) , an innovation platform dedicated to accelerating promising health innovations, has reported that its Acquisition target, Evofem Biosciences (OTCQB: EVFM) , a women's health ...

MOUNTAIN VIEW, Calif., September 24, 2024--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating promising health innovations, today announced ...

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, and its majority-owned subsidiary, Pearsanta Inc., have signed a market development collaboration ...

MOUNTAIN VIEW, Calif. & SAN DIEGO--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating ...

Aditxt, Inc., a pharmaceutical company specializing in immune system reprogramming, has entered into a series of strategic agreements, as per a recent 8-K filing with the Securities and Exchange ...

Pearsanta’s MET is Seeking to Become the First and Only Validated and Commercialized Blood-based Biomarker Test for Endometriosis Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company ...

Aditxt (NASDAQ: ADTX) , a company dedicated to discovering, developing and deploying promising <a target=_blank href= ...

Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that it ...

Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating promising health innovations, today announced that its majority-owned subsidiary, Pearsanta, ...

Aditxt, Inc., a pharmaceutical company specializing in immune system reprogramming, has entered into a series of strategic agreements, as per a recent 8-K filing with the Securities and Exchange ...